Syntara (SNT) Investor presentation summary

Company overview and investment highlights

• Clinical-stage drug developer focused on first- and best-in-class therapies, with a lead asset, amsulostat, targeting myelofibrosis and holding FDA IND and orphan drug designation.

• Backed by specialist healthcare investors, with 44% institutional ownership and $11.5m in non-dilutive grant funding over the last three years.

• Experienced management and board with a strong track record in licensing and asset sales, raising $100m and executing three deals worth ~$100m.

• Funded into 2027, with a proforma cash position of $20.3m as of December 2025, and multiple near-term clinical catalysts expected in the next 12–18 months.

Lead asset: amsulostat in myelofibrosis

• Amsulostat is a pan-LOX inhibitor with a differentiated safety and efficacy profile, showing potential for disease modification in myelofibrosis patients unresponsive to standard care.

• Phase 2a data showed 73% of patients achieved ≥50% symptom reduction at 24 weeks, and 44% achieved significant spleen volume reduction.

• No drug-related serious adverse events reported; majority of adverse events were mild.

• FDA has provided positive feedback on the Phase 2b trial protocol, with trial commencement expected in Q4 2026.

• Strong interest from strategic partners, with recent comparable deals in the sector ranging from $1.1B to $2.9B.

Pipeline and clinical development

• Additional assets include SNT-9465 for hypertrophic scarring (results due H2 2026) and SNT-4728 for IRBD/Parkinson's Disease (top-line data expected Q2 2026).

• Two ongoing Phase 1b/2a studies in myelodysplastic syndrome (MDS) with data expected in H2 2026.

• SNT-4728 Phase 2 study in iRBD is fully recruited, with results expected Q2 2026; study funded by Parkinson's UK.

• Clinical proof of concept for LOX inhibition in skin scarring achieved, with significant improvements in scar structure and vascularization.